Abstract 188P
Background
Soft tissue sarcomas (STS) are a group of rare and heterogeneous tumors with different clinical and biological behaviors. Better prognosis has been associated to an inflamed tumor microenvironment (TME) characterized by the presence of tertiary lymphoid structures (TLS) and B cells. However, the cellular and molecular mechanisms underlying these clinical associations have not been elucidated yet.
Methods
TME composition and TLS quantification were assessed by sequential IHC with αCD3, αCD20, αCD23 and αCD68 antibodies on specimens obtained from patients with primary or locally recurrent STS enrolled and treated at the Careggi Hospital (RESEARCH study). TME transcriptomic profiling was performed using the nCounter Immunology Panel by NanoString. RNA-sequencing and clinical data for 206 STS patients were retrieved from the TCGA SARC project.
Results
IHC of 23 treatment-naïve STS specimens showed higher TLS density and incidence in the group of non-recurrent patients (11/15) compared to patients developing recurrence (2/8; P=0.039). CD8+ T cell, CD20+ B cell and CD23+ follicular dendritic cell densities are higher in the TME of TLS+ STS. CD20 and CD23 (but not CD8) expression is associated to improved recurrence-free survival (RFS) and overall survival (OS) in our cohort. Transcriptomic analysis of 31 treatment-naïve STSs showed that high expression of genes discriminating for germinal center (GC) B cells correlated to the upregulation of Th17-related genes, and decreased expression of M2-like tumor-associated macrophages (TAMs)-related genes. High expression of GC B cell- and Th17 differentiation-related signatures showed associations to longer RFS in our cohort, and to improved OS in the TCGA SARC cohort. Analysis of 5 samples obtained after neoadjuvant radiotherapy (RT) showed reduced expression of IL17A and GC B-related genes while increased TAM-related gene expression, compared to paired biopsies obtained before RT.
Conclusions
Our data identified a prognostic value for Th17-related genes, suggest a potential crosstalk between GC B cells and Th17 cells in coordinating antitumor immune responses, and a potential role for M2-like TAMs (and RT) in inhibiting TLS formation in STS.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
182P - Multi-modal artificial intelligence outperforms image-based approaches for mutation prediction from H&E tissue images in colorectal cancer
Presenter: Marc Päpper
Session: Poster session 08
183P - Development of a cadherin-17 (CDH17) immunohistochemistry assay for use as a companion diagnostic for cabotamig in gastrointestinal cancers
Presenter: Dennis Wong
Session: Poster session 08
184P - From breast and gastric to beyond: Expanding HER2 detection in solid tumors using quantitative RNA and protein analysis
Presenter: Kristian Egebjerg
Session: Poster session 08
185P - Multi-omics profiling and clinical characterization of colon-like cancer of unknown primary (CUP)
Presenter: Maria Pouyiourou
Session: Poster session 08
186P - Differences in antigen and immune marker expression in lymphoepithelioma-like carcinoma (LELC) and nasopharyngeal carcinoma (NPC): A multiplex immunohistochemistry (mIHC), spatial transcriptomic and multiplex immunofluorescence (mIF)-based analysis
Presenter: Daniel Peh
Session: Poster session 08
187P - Organoid growth-based oncological sensitivity test (OncoSensi) for predicting radiation therapy outcomes in pharyngeal and esophageal cancer
Presenter: Dong Woo Lee
Session: Poster session 08
189P - An image-based deep learning prediction model for characterization of the drug tolerant persister cell state
Presenter: Lauren Cech
Session: Poster session 08
190P - A large scale proteogenomics atlas for precision oncology research
Presenter: Timothy Anthony Yap
Session: Poster session 08
191P - Understanding and overcoming resistance to selective FGFR inhibitors across FGFR2-driven tumors
Presenter: Francesco Facchinetti
Session: Poster session 08
192P - Use of biosimulation to predict homologous recombination deficiency and PARPi benefit in patients with ovarian, pancreatic, prostate and triple negative breast cancers
Presenter: Daniel Palmer
Session: Poster session 08